Boston Scientific Corporation (BSX)

NYSE: BSX · Real-Time Price · USD
102.36
-0.68 (-0.66%)
Jan 31, 2025, 4:00 PM EST - Market closed
-0.66%
Market Cap 150.86B
Revenue (ttm) 15.91B
Net Income (ttm) 1.79B
Shares Out 1.47B
EPS (ttm) 1.21
PE Ratio 84.67
Forward PE 37.74
Dividend n/a
Ex-Dividend Date n/a
Volume 4,504,011
Open 103.40
Previous Close 103.04
Day's Range 102.32 - 103.60
52-Week Range 64.08 - 103.60
Beta 0.80
Analysts Strong Buy
Price Target 98.95 (-3.33%)
Earnings Date Feb 5, 2025

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, c... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date May 18, 1992
Employees 48,000
Stock Exchange NYSE
Ticker Symbol BSX
Full Company Profile

Financial Performance

In 2023, Boston Scientific's revenue was $14.24 billion, an increase of 12.29% compared to the previous year's $12.68 billion. Earnings were $1.57 billion, an increase of 144.55%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $98.95, which is a decrease of -3.33% from the latest price.

Price Target
$98.95
(-3.33% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Top 4 Health Care Stocks You May Want To Dump In Q1

As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: BBIOISRGITCI
11 days ago - Benzinga

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Abl...

16 days ago - PRNewsWire

Boston Scientific Jumps Ahead of Earnings

Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.

17 days ago - FXEmpire

Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific

The Investment Committee discuss some stocks on the move today.

Other symbols: CEGDALSGWYNN
22 days ago - CNBC Television

Final Trades: Apollo, UnitedHealth, Boston Scientific and the IYF

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: UNHAPOIYF
24 days ago - CNBC Television

Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal

On Wednesday, Boston Scientific Corporation BSX agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral arte...

24 days ago - Benzinga

Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.

Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease MARLBOROUGH...

24 days ago - PRNewsWire

Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results

MARLBOROUGH, Mass. , Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P.

4 weeks ago - PRNewsWire

Boston Scientific Corporation: Solid Financials And Upward Continuation

Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. The smooth upward movement of the stock indicates the quality of its investor base. Stro...

4 weeks ago - Seeking Alpha

FDA classifies recall of Boston Scientific catheters as 'most serious'

The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's catheters used in a type of minimally invasive surgery as "most serious".

6 weeks ago - Reuters

Boston Scientific CMO Discuss Solutions for Health Inequality on Today's Marketplace

NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Boston Scientific (NYSE: BSX) Global Chief Medical Officer, Kenneth Stein, MD, and Sco...

7 weeks ago - PRNewsWire

Jim Cramer talks companies that joined the $100 billion club this year

'Mad Money' host Jim Cramer looks at companies that joined the $100 billion club this year.

Other symbols: ANETAPPARMCETNFIPANW
7 weeks ago - CNBC Television

The Best Large-Cap Stocks to Buy

Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.

2 months ago - Kiplinger

Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.

Acquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases MARLBOROUGH, Mass. , Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (...

2 months ago - PRNewsWire

Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?

On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.

2 months ago - Benzinga

Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO , ...

2 months ago - PRNewsWire

Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)

Boston Scientific Corporation (NYSE:BSX) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-An...

2 months ago - Seeking Alpha

Boston Scientific Closes Acquisition of Axonics, Inc.

MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company ...

Other symbols: AXNX
2 months ago - PRNewsWire

Kidney Stone Management Market Forecast Report, 2024-2032 - Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global market size for kidn...

3 months ago - GlobeNewsWire

Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference

MARLBOROUGH, Mass. , Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.

3 months ago - PRNewsWire

Boston Scientific Announces Agreement to Acquire Cortex, Inc.

Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass. , Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporat...

3 months ago - PRNewsWire

Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph...

3 months ago - Seeking Alpha

Why The Fundamentals Make Me Bullish On Boston Scientific

Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more...

3 months ago - Seeking Alpha

Why is Boston Scientific Stock Trading Lower On Wednesday?

On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic s...

3 months ago - Benzinga

ACURATE neo2™ Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024

MARLBOROUGH, Mass. and WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which...

3 months ago - PRNewsWire